Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- RGNX
- Price
- 5.94
- Stock movement down
- -0.22 (-3.57%)
- Company name
- Regenxbio Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 294.30M
- Ent value
- 455.38M
- Price/Sales
- 3.49
- Price/Book
- 0.98
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- -66.06%
- 3 year return
- -41.88%
- 5 year return
- -29.55%
- 10 year return
- -
Last updated: 2025-04-18
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
RGNX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.49 |
| Price to Book | 0.98 |
| EV to Sales | 5.40 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 49.55M |
| EPS (TTM) | -4.70 |
| FCF per share (TTM) | -3.64 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 84.33M |
| Gross profit (TTM) | 33.27M |
| Operating income (TTM) | -243.78M |
| Net income (TTM) | -238.81M |
| EPS (TTM) | -4.70 |
| EPS (1y forward) | -0.81 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 39.46% |
| Operating margin (TTM) | -289.09% |
| Profit margin (TTM) | -283.19% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 56.62M |
| Net receivables | 25.18M |
| Total current assets | 313.40M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 245.19M |
| Total assets | 519.11M |
| Accounts payable | 19.52M |
| Short/Current long term debt | 84.06M |
| Total current liabilities | 102.72M |
| Total liabilities | 217.70M |
| Shareholder's equity | 301.42M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -182.26M |
| Capital expenditures (TTM) | 2.48M |
| Free cash flow (TTM) | -184.74M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -79.23% |
| Return on Assets | -46.00% |
| Return on Invested Capital | -77.25% |
| Cash Return on Invested Capital | -59.76% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 6.10 |
| Daily high | 6.31 |
| Daily low | 5.91 |
| Daily Volume | 648K |
| All-time high | 82.15 |
| 1y analyst estimate | 36.00 |
| Beta | 1.23 |
| EPS (TTM) | -4.70 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 6 May 2025 |
Downside potential
Loading...
Downside potential data
| RGNX | S&P500 | |
| Current price drop from All-time high | -92.77% | -14.12% |
| Highest price drop | -93.54% | -56.47% |
| Date of highest drop | 8 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -54.26% | -11.07% |
| Avg time to new high | 67 days | 12 days |
| Max time to new high | 1704 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
294.30M
Marketcap category
Small-cap
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
Employees
344
Website
Investor relations
-
SEC filings
CEO
Kenneth T. Mills
Country
USA
City
Rockville
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
No events found
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page